GSK plc (LON:GSK) Receives Consensus Recommendation of “Hold” from Analysts

Shares of GSK plc (LON:GSK) have been given a consensus rating of “Hold” by the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is GBX 1,917.86.

Several equities research analysts have commented on the stock. Shore Capital Group restated a “buy” rating and set a GBX 2,300 target price on shares of GSK in a research report on Wednesday, February 4th. Citigroup boosted their price objective on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a report on Monday, February 9th. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a report on Friday, January 23rd. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 price target on shares of GSK in a research report on Wednesday, January 7th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th.

Insider Activity

In other news, insider Luke Miels sold 4,549 shares of GSK stock in a transaction on Monday, February 9th. The stock was sold at an average price of GBX 2,211, for a total transaction of £100,578.39. Also, insider Wendy Becker acquired 441 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was acquired at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. Insiders bought a total of 4,597 shares of company stock worth $9,082,343 over the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

GSK Stock Performance

LON GSK opened at GBX 2,227.40 on Tuesday. The stock has a market capitalization of £89.87 billion, a price-to-earnings ratio of 16.75, a PEG ratio of 1.24 and a beta of 0.31. The business’s 50 day moving average is GBX 1,888.13 and its two-hundred day moving average is GBX 1,702.91. GSK has a 12-month low of GBX 1,242.50 and a 12-month high of GBX 2,230. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Research analysts expect that GSK will post 175.980975 EPS for the current year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.